Kinetic Profile of Miocamycin in Middle Ear Fluid and Mucosa

Abstract

A group of 18 patients, before undergoing otoplastic surgery, was treated with miocamycin 600 mg in a single dose; middle ear tissue samples were collected at 2, 3, 4 and 6 h. a group of 20 patients suffering from secretory otitis media (SOM) was also treated with 600 mg of miocamycin in a single dose; collections of middle ear fluid (MEF) were performed at 1, 2, 4 and 6 h. Blood withdrawals from all patients occurred at the same time intervals. the miocamycin determination was performed by means of a microbiological method employing Sarcina lutea ATCC 9341. the highest serum levels (1.06 ± 0.13 mg/1) were found at 2 h in the group from which middle ear mucosa had been withdrawn and at 1 h (2.2 ± 0.5 mg/1) in the group from which the MEF had been collected; at 6 h miocamycin could be determined in both groups, with values ranging from 0.1 to 0.2 mg/1. in middle ear mucosa the miocamycin concentration was 1.52 ± 0.27 mg/kg at 2 h and 0.2 ± 0.09 mg/kg at 6 h. in MEF, the miocamycin concentration was 2.1 ± 0.27 mg/1 at 1 h and 0.24 ± 0.05 mg/1 at 6 h. the miocamycin concentration determined at 1 h in MEF was virtually equal to that in serum at the same time. at the following experimental times of withdrawal, the miocamycin concentration in mucosa specimens, as well as in MEF samples, proved to be markedly higher than values simultaneously found in serum.

Key Words:

• pharmacokinetics
• tissue levels
• macrolides
• miocamycin